{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:01:11Z","timestamp":1754398871878},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Human papillomavirus (HPV) causes cervical cancer and external genital warts. The purpose of this study is to document the genotype distribution of HPV in females aged between 18 and 34 who self-referred to an STI clinic with visible external genital warts (EGW). Scrapings were taken from visible external genital warts (EGW). These scrapings were analysed by PCR for the presence of HPV DNA. Positive samples were then genotyped by means of a commercially available assay (LiPA). A comparison of genotyping results determined by the LiPA assay and direct amplicon DNA sequencing was also performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Ninety-two patients out of 105 samples (88%) had detectable levels of HPV DNA. The majority of individuals with EGW (66%) showed the presence of two or more genotypes. The most common HPV genotypes present in the study population were HPV-6, HPV-11, HPV-16, HPV-18, HPV-33 and HPV-53. Potential effects of vaccination on HPV molecular epidemiology indicate that 40% of the patients could have been protected from the high risk genotypes HPV-16 and HPV-18.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This is the first report of the molecular epidemiology of external genital warts in women aged between 18 and 34 from Ireland based on results from a LiPA assay. The study shows that most individuals are infected with multiple genotypes including those with high oncogenic potential and that the newly available HPV vaccines could have a significant impact on prevalence of the most common HPV genotypes in this study population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-6-112","type":"journal-article","created":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T18:14:12Z","timestamp":1248372852000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland"],"prefix":"10.1186","volume":"6","author":[{"given":"John F","family":"Menton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M","family":"Cremin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydie","family":"Canier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam J","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,23]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.2741\/1971","volume":"11","author":"ZM Zheng","year":"2006","unstructured":"Zheng ZM, Baker CC: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006, 11: 2286-2302. 10.2741\/1971","journal-title":"Front Biosci"},{"issue":"Suppl 3","key":"626_CR2","first-page":"S3\/1","volume":"24","author":"N Munoz","year":"2006","unstructured":"Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006,24(Suppl 3):S3\/1-10.","journal-title":"Vaccine"},{"key":"626_CR3","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","volume":"37","author":"DR Brown","year":"1999","unstructured":"Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH: Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37: 3316-3322.","journal-title":"J Clin Microbiol"},{"key":"626_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189: 12-19. 10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","journal-title":"J Pathol"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMicm010103","volume":"348","author":"T Meyer","year":"2003","unstructured":"Meyer T, Stockfleth E: Classification of human papillomavirus. N Engl J Med 2003, 348: 2040-2041. author reply 2040\u20132041. 10.1056\/NEJM200305153482022","journal-title":"N Engl J Med"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00019053-200523110-00004","volume":"23","author":"RP Insinga","year":"2005","unstructured":"Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23: 1107-1122. 10.2165\/00019053-200523110-00004","journal-title":"Pharmacoeconomics"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0090-8258(03)00466-9","volume":"90","author":"TJ Herzog","year":"2003","unstructured":"Herzog TJ: New approaches for the management of cervical cancer. Gynecol Oncol 2003, 90: S22-27. 10.1016\/S0090-8258(03)00466-9","journal-title":"Gynecol Oncol"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nrc1973","volume":"6","author":"R Roden","year":"2006","unstructured":"Roden R, Wu TC: How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006, 6: 753-763. 10.1038\/nrc1973","journal-title":"Nat Rev Cancer"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1016\/j.vaccine.2007.01.013","volume":"25","author":"JT Bryan","year":"2007","unstructured":"Bryan JT: Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007, 25: 3001-3006. 10.1016\/j.vaccine.2007.01.013","journal-title":"Vaccine"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367: 1247-1255. 10.1016\/S0140-6736(06)68439-0","journal-title":"Lancet"},{"key":"626_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/JCM.38.1.357-361.2000","volume":"38","author":"PE Gravitt","year":"2000","unstructured":"Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38: 357-361.","journal-title":"J Clin Microbiol"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1128\/JCM.02098-06","volume":"45","author":"V Fontaine","year":"2007","unstructured":"Fontaine V, Mascaux C, Weyn C, Bernis A, Celio N, Lefevre P, Kaufman L, Garbar C: Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol 2007, 45: 928-934. 10.1128\/JCM.02098-06","journal-title":"J Clin Microbiol"},{"key":"626_CR13","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/j.1525-1438.2007.01157.x","volume":"18","author":"T Matsukura","year":"2008","unstructured":"Matsukura T, Sugase M: Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer 2008, 18: 1042-1050. 10.1111\/j.1525-1438.2007.01157.x","journal-title":"Int J Gynecol Cancer"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI28607","volume":"116","author":"DR Lowy","year":"2006","unstructured":"Lowy DR, Schiller JT: Prophylactic human papillomavirus vaccines. J Clin Invest 2006, 116: 1167-1173. 10.1172\/JCI28607","journal-title":"J Clin Invest"},{"key":"626_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.clindermatol.2004.07.003","volume":"22","author":"N Dupin","year":"2004","unstructured":"Dupin N: Genital warts. Clin Dermatol 2004, 22: 481-486. 10.1016\/j.clindermatol.2004.07.003","journal-title":"Clin Dermatol"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","volume":"369","author":"EA Joura","year":"2007","unstructured":"Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369: 1693-1702. 10.1016\/S0140-6736(07)60777-6","journal-title":"Lancet"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Munoz","year":"2003","unstructured":"Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348: 518-527. 10.1056\/NEJMoa021641","journal-title":"N Engl J Med"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-6-112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:21:25Z","timestamp":1630459285000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-6-112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,23]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-6-112","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,23]]},"assertion":[{"value":"5 June 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"112"}}